Periodic Reporting for period 1 - VALPAS (VALidation of human PApilloma virus assays on Self-collected first void urine samples)
Reporting period: 2015-09-01 to 2015-10-31
VALPAS specific objectives were formulated as: (1) validate and prioritize market segments and EU-28 countries to launch Colli-Pee™, (2) validate business model and positioning of Colli-Pee™ versus competing products, (3) business plan quantification and timing, (4) assessment of usability of different diagnostic assays on first void urine for HPV testing.
*Market segment analysis, consisting of (1) market introduction strategy allowing stepwise implementation of Colli-Pee™ for HPV-based cervical cancer screening, (2) identification of market barriers (social, industrial, technical, economical) and counter-measurements, and (3) identification of user / end-user needs and willingness to use.
*Validation of business model, consisting of (1) thorough information about competing solutions, (2) identification of key stakeholders and value for money (3) insights in organisation of screening programmes (4) new and strengthened partnerships with diagnostic companies and laboratories, (5) validated distribution channels & new production facilities, and (6) validated pricing strategy.
*Updated business plan, based on information of previous two tasks, consisting of a commercialization plan and exploitation plan. These include a.o. financial requirements to reach the commercialisation stage.
*Assessment of diagnostic assays on first void urine for HPV testing, consisting of (1) a selection of PCR-based assays from top 10 diagnostic companies, (2) an established network to perform clinical trials in 5 EU countries, allowing the comparison of Colli-Pee™ to other self-sampling devices and clinician-based sampling (3) determination of clinical accuracy.
This approach will allow increasing the participation rate of women in cervical screening programmes worldwide. Ultimately, prevalence of cervical cancer can be reduced and health care costs decreased. In the end, no one wants to loose a relative or friend from cervical cancer.